Panel Discussion

Monday, March 9, 2026

9:50 AM - 10:10 AM EST

Location: Spotlight Theater

Moderator(s)

Lawrence Biegelsen, MBA

Managing Director Medical Supplies & Devices
Wells Fargo
Short Hills, New Jersey, United States

Disclosure information not submitted.
Rick Wise, CFA

Research Analyst
Stifel
New York, New York, United States

Disclosure information not submitted.

Panel Discussant(s)

Nina Goodheart, MBA

SVP & President
Structural Heart & Aortic - Medtronic
Doylestown, Pennsylvania, United States

Disclosure information not submitted.
Eberhard Grube, MD, MSCAI

Head CIIC
University Hospital Bonn
Bonn, Nordrhein-Westfalen, Germany

Disclosure information not submitted.
Jeffrey J. Popma, MD

Chief Scientific Officer
CRF
Newton, Massachusetts, United States

Disclosure(s): Medtronic: CMO ended Nov 2024 (Terminated, November 1, 2024), Stock-publicly held company (excluding mutual/index funds) (Terminated, November 1, 2024)
Michael J. Reardon, MD

Professor and Allison Family Distinguished Chair of Cardiovascular Research
Houston Methodist DeBakey Heart & Vascular Center
Houston, Texas, United States

Disclosure(s): BSCI: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); High Life: Consulting Fees (e.g., advisory boards) (Ongoing); JValve: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Siemens: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); WL Gore & Associates: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Lars Sondergaard, MD

Chief Medical Officer
Abbott Structural Heart
Santa Clara, California, United States

Disclosure(s): Abbott: Employee (Ongoing)
Mark A. Turco, MD

President & CEO
RI Life Science Hub
Providence, Rhode Island, United States

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Jeffrey J. Popma, MD: Medtronic: CMO ended Nov 2024 (Terminated, November 1, 2024), Stock-publicly held company (excluding mutual/index funds) (Terminated, November 1, 2024)

Michael J. Reardon, MD: BSCI: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); High Life: Consulting Fees (e.g., advisory boards) (Ongoing); JValve: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Siemens: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); WL Gore & Associates: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Lars Sondergaard, MD: Abbott: Employee (Ongoing)

Mark A. Turco, MD: No financial relationships to disclose